Breaking News, Collaborations & Alliances

Ymir Partners With OHSU Cancer Institute to Develop Urinary Biomarkers

The development will help detect hepatocellular carcinoma in at-risk patients

Ymir Genomics, LLC and the Knight Cancer Institute at Oregon Health & Science University (OHSU) are collaborating to develop urinary biomarkers that will help detect hepatocellular carcinoma (HCC) in at-risk patients.    The development starts with Ymir, who will isolate extracellular vesicles and analyze miRNA profiles of urine samples from liver cancer patients and high-risk cirrhotic patient controls provided by OHSU. OHSU will then take the same vesicle preps and determine protei...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters